AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL

NCT07717177 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Large B-Cell Lymphoma (LBCL)

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Rituximab (R)
DRUG: Zanubrutinib
DRUG: Lenalidomide
DRUG: Glofitamab

Sponsor

Ruijin Hospital